

40 anni di attività di produzione di farmaci farmaceutici



MERGERSCORP

40 anni di attività di produzione di farmaci farmaceutici

L'azienda in vendita è un'azienda sanitaria con sede a Bangalore, in India. L'azienda si occupa della produzione e della fornitura di farmaci e integratori alimentari a persone di tutto il mondo (standard di qualità specificati dalle certificazioni OMS-GMP e ISO).

L'azienda è dotata di un'unità certificata ISO 9001 e OMS GMP, che soddisfa gli ordini provenienti da paesi come America Centrale, Nigeria, Bangladesh, Cambogia, Sri Lanka, Malesia, Repubblica Dominicana ecc. L'unità dispone di oltre 50000 piedi quadrati di area edificata dedicata alla produzione di compresse, capsule e liquidi orali.

L'azienda produce prodotti generici, nutraceutici e medicinali a base di erbe.

Risultati finanziari in evidenza (3 anni)

Il fatturato ha registrato un aumento costante negli ultimi 3 anni, ma con una riduzione dell'EBITDA. La riduzione dell'EBITDA è dovuta all'aumento della spesa pubblicitaria per un marchio online avviato 5 anni fa. Tutti i profitti ottenuti da questo marchio di integratori D2C vengono reinvestiti nel marketing del marchio, il che ha portato a una riduzione dell'EBITDA dell'intera azienda.

Prodotti

438 licenze di produzione di farmaci generici. Di questi, l'azienda detiene attualmente 148 approvazioni CoPP che ci permettono di registrare i nostri prodotti per l'esportazione in diversi paesi del ROW.

Vantaggio competitivo globale

Elevata capacità produttiva per un impianto di produzione su piccola scala con un vantaggio in termini di costi. L'unità produttiva situata all'interno della città di Bangalore consente l'accesso a manodopera sia qualificata che non qualificata.

TARGET PRICE

\$12,000,000

GROSS REVENUE

\$1,900,000

EBITDA

\$0

BUSINESS TYPE

Farmaceutico

ESTABLISHED

1982

SUPPORT & TRAINING

1 year

COUNTRY

India

BUSINESS ID

L#20210016

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM